Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine.

Bayliss MAJ, Rigdova K, Kyriakides M, Grier S, Lovering AM, Williams H, Griffith DC, MacGowan A.

J Pharm Biomed Anal. 2019 May 30;169:90-98. doi: 10.1016/j.jpba.2019.02.036. Epub 2019 Feb 26.

2.

Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.

Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, Gaur AH, Mathews WC, Beil R, Korthuis PT, Nijhawan AE, Rutstein RM, Agwu AL; HIV Research Network.

HIV Med. 2019 Feb;20(2):169-174. doi: 10.1111/hiv.12695. Epub 2018 Dec 18.

PMID:
30561888
3.

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01659-18. doi: 10.1128/AAC.01659-18. Print 2019 Jan.

PMID:
30397063
4.

Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model.

Tarazi Z, Sabet M, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01671-18. doi: 10.1128/AAC.01671-18. Print 2019 Feb.

PMID:
30397059
5.

Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Sabet M, Tarazi Z, Griffith DC.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01665-18. doi: 10.1128/AAC.01665-18. Print 2019 Jan.

PMID:
30323049
6.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

7.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

8.

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01969-17. doi: 10.1128/AAC.01969-17. Print 2018 Feb.

9.

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01446-17. doi: 10.1128/AAC.01446-17. Print 2018 Jan.

10.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
11.

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Weiss WJ, Pulse ME, Nguyen P, Peterson K, Silva J, Simecka JW, Valtierra D, Sabet M, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01439-17. doi: 10.1128/AAC.01439-17. Print 2018 Jan.

12.

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure.

Lodise TP, Fan W, Griffith DC, Dudley MN, Sulham KA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01165-17. doi: 10.1128/AAC.01165-17. Print 2018 Jan.

13.

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov.

14.

Premature Coronary Artery Disease and ST-Elevation Myocardial Infarction in a 24-Year-Old Man With Perinatally Acquired Human Immunodeficiency Virus: A Case Report.

Griffith DC, Aronis KN, Orozco AM, Traill TA, Manabe YC, Agwu AL.

Open Forum Infect Dis. 2017 Feb 10;4(1):ofw260. doi: 10.1093/ofid/ofw260. eCollection 2017 Winter.

15.

Caring for youth living with HIV across the continuum: turning gaps into opportunities.

Griffith DC, Agwu AL.

AIDS Care. 2017 Oct;29(10):1205-1211. doi: 10.1080/09540121.2017.1290211. Epub 2017 Feb 13. Review.

16.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.

Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6326-32. doi: 10.1128/AAC.00568-16. Print 2016 Oct.

17.

Knowledge of HPV among HIV-Infected and HIV-Uninfected Adolescent Women in South Africa.

Griffith DC, Adler D, Wallace M, Bennie T, Abar B, Bekker LG.

J Womens Health Issues Care. 2015;4(5). pii: 1000203. Epub 2015 Sep 23.

18.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

19.

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN.

J Med Chem. 2015 May 14;58(9):3682-92. doi: 10.1021/acs.jmedchem.5b00127. Epub 2015 Mar 17.

PMID:
25782055
20.

Thermolysis of microalgae and duckweed in a CO₂-swept fixed-bed reactor: bio-oil yield and compositional effects.

Campanella A, Muncrief R, Harold MP, Griffith DC, Whitton NM, Weber RS.

Bioresour Technol. 2012 Apr;109:154-62. doi: 10.1016/j.biortech.2011.12.115. Epub 2012 Jan 5.

PMID:
22285294
21.

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.

Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN.

Antimicrob Agents Chemother. 2011 Jun;55(6):2636-40. doi: 10.1128/AAC.01744-10. Epub 2011 Mar 28.

22.

Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections.

Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN.

FEMS Immunol Med Microbiol. 2011 Mar;61(2):141-6. doi: 10.1111/j.1574-695X.2010.00755.x. Epub 2010 Nov 12.

23.

Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.

King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN.

Diagn Microbiol Infect Dis. 2010 Feb;66(2):181-6. doi: 10.1016/j.diagmicrobio.2009.09.009. Epub 2009 Oct 13.

PMID:
19828274
24.

In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.

King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN.

Antimicrob Agents Chemother. 2010 Jan;54(1):143-8. doi: 10.1128/AAC.00248-09. Epub 2009 Oct 5.

25.

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.

Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2009 Sep;53(9):3923-8. doi: 10.1128/AAC.00268-09. Epub 2009 Jun 15.

26.

Aerosol antibiotics: considerations in pharmacological and clinical evaluation.

Dudley MN, Loutit J, Griffith DC.

Curr Opin Biotechnol. 2008 Dec;19(6):637-43. doi: 10.1016/j.copbio.2008.11.002. Epub 2008 Nov 25. Review.

PMID:
19036576
27.

Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.

Griffith DC, Rodriguez D, Corcoran E, Dudley MN.

Antimicrob Agents Chemother. 2008 Jan;52(1):244-7. Epub 2007 Oct 22.

28.

Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization.

Watkins WJ, Chong L, Cho A, Hilgenkamp R, Ludwikow M, Garizi N, Iqbal N, Barnard J, Singh R, Madsen D, Lolans K, Lomovskaya O, Oza U, Kumaraswamy P, Blecken A, Bai S, Loury DJ, Griffith DC, Dudley MN.

Bioorg Med Chem Lett. 2007 May 15;17(10):2802-6. Epub 2007 Feb 27.

PMID:
17350259
29.

Review of reported cholera outbreaks worldwide, 1995-2005.

Griffith DC, Kelly-Hope LA, Miller MA.

Am J Trop Med Hyg. 2006 Nov;75(5):973-7. Review.

PMID:
17123999
30.

Skin problems related to the occupation of commercial fishing in North Carolina.

Burke WA, Griffith DC, Scott CM, Howell ER.

N C Med J. 2006 Jul-Aug;67(4):260-5.

PMID:
17066654
31.

Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?

Griffith DC, Corcoran E, Lofland D, Lee A, Cho D, Lomovskaya O, Dudley MN.

Antimicrob Agents Chemother. 2006 May;50(5):1628-32.

32.

In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria.

Griffith DC, Harford L, Williams R, Lee VJ, Dudley MN.

Antimicrob Agents Chemother. 2003 Jan;47(1):43-7.

Supplemental Content

Loading ...
Support Center